Encelle

Encelle, founded in 1995, was a development-stage company that specialized in therapeutic and clinical products for tissue repair and regeneration. The company's core technology was a patented injectable biopolymer, E-Matrix™, designed for a wide range of therapeutic applications. These applications included dermal healing for wounds like diabetic foot ulcers, bone repair for spinal fusion, connective tissue repair for tendons and ligaments, and soft tissue augmentation for cosmetic surgery.

The company's business model focused on the pre-clinical and early clinical development of its E-Matrix™ product. Encelle actively sought corporate partnerships to co-develop and out-license products for its various targeted indications. A notable partnership was an exclusive worldwide commercialization agreement with Smith & Nephew, PLC, for the use of E-Matrix™ in treating cutaneous wounds. The firm raised at least $17.9M in funding from investors including Band of Angels, Coastal Growth Partners, Cordova Ventures, Hibernia Capital Partners, and Intersouth Partners.

In June 2007, Encelle was acquired by Pioneer Surgical Technology (now Resolve Surgical Technologies). Following the acquisition, Encelle was renamed Pioneer Surgical Orthobiologics and became a wholly-owned subsidiary, continuing its operations and development activities. The acquisition provided Pioneer Surgical an entry into the orthobiologics market.

Keywords: tissue regeneration, injectable biopolymer, clinical development, regenerative medicine, wound healing, dermal healing, bone repair, cosmetic surgery, connective tissue repair, orthobiologics, E-Matrix, biopolymer, therapeutic products, soft tissue augmentation, drug discovery, biotechnology, medical devices, surgical technologies